Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  1. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Transcriptomic Fingerprint of Bacterial Infection in Lower Extremity Ulcers

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Tocilizumab (TCZ), a monoclonal antibody targeting the human interleukin-6-receptor (IL-6R), is indicated for the treatment of rheumatoid arthritis (RA). We examined whether three IL6R single-nucleotide polymorphisms rs12083537, rs2228145 (formerly rs8192284), and rs4329505 with previously reported functional effects were associated with clinical response to TCZ in a retrospective study cohort consisting of 79 RA patients. Three months after initiation of TCZ therapy, changes in swollen joint count (SJC) and, subordinately, tender joint count (TJC), serum-CRP, DAS28-CRP, and EULAR-response were tested for association with the IL6R-haplotype or genotype. The major allele (A) of rs12083537 and the minor allele (C) of rs4329505 were associated with a poor SJC response (P=0.02 and 0.02, respectively). Moreover, the AAC-haplotype (for rs12083537, rs2228145, and rs4329505, respectively) was associated with a poor SJC response (P=0.00004) and, with borderline significance, EULAR-response (P=0.05). These data suggest that genetic variation in IL6R may aid in predicting TCZ therapy outcome in RA patients.

Original languageEnglish
JournalPharmacogenetics and Genomics
Volume24
Issue number8
Pages (from-to)401-5
Number of pages5
ISSN1744-6872
DOIs
Publication statusPublished - Aug 2014

    Research areas

  • Adult, Aged, Aged, 80 and over, Alleles, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Rheumatoid, Female, Haplotypes, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Receptors, Interleukin-6, Retrospective Studies, Young Adult

ID: 44959278